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Abstract
In ST elevation myocardial infarction (STEMI) context, clinical studies have shown the dele-
terious effect of high aldosterone levels on ventricular arrhythmia occurrence and cardiac
mortality. Previous in vitro reports showed that during ischemia-reperfusion, aldosterone
modulates K+ currents involved in the holding of the resting membrane potential (RMP).
The aim of this study was to assess the electrophysiological impact of aldosterone on IK1
current during myocardial ischemia-reperfusion. We used an in vitromodel of “border zone”
using right rabbit ventricle and standard microelectrode technique followed by cell-attached
recordings from freshly isolated rabbit ventricular cardiomyocytes. In microelectrode experi-
ments, aldosterone (10 and 100 nmol/L, n=7 respectively) increased the action potential
duration (APD) dispersion at 90% between ischemic and normoxic zones (from 95±4 ms to
116±6 ms and 127±5 ms respectively, P<0.05) and reperfusion-induced sustained prema-
ture ventricular contractions occurrence (from 2/12 to 5/7 preparations, P<0.05). Con-
versely, potassium canrenoate 100 nmol/L and RU 28318 1 μmol/l alone did not affect AP
parameters and premature ventricular contractions occurrence (except Vmax which was
decreased by potassium canrenoate during simulated-ischemia). Furthermore, aldosterone
induced a RMP hyperpolarization, evoking an implication of a K+ current involved in the
holding of the RMP. Cell-attached recordings showed that aldosterone 10 nmol/L quickly
activated (within 6.2±0.4 min) a 30 pS K+-selective current, inward rectifier, with pharmaco-
logical and biophysical properties consistent with the IK1 current (NPo =1.9±0.4 in control vs
NPo=3.0±0.4, n=10, P<0.05). These deleterious effects persisted in presence of RU 28318,
a specific MR antagonist, and were successfully prevented by potassium canrenoate, a non
specific MR antagonist, in both microelectrode and patch-clamp recordings, thus indicating
a MR-independent IK1 activation. In this ischemia-reperfusion context, aldosterone induced
rapid and MR-independent deleterious effects including an arrhythmia substrate (increased
APD90 dispersion) and triggered activities (increased premature ventricular contractions
occurrence on reperfusion) possibly related to direct IK1 activation.
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Introduction
Aldosterone and mineralocorticoid receptor (MR) activation have an important pathophysio-
logical role in cardiovascular events occurrence [1–4]. Furthermore, clinical studies have
shown that high aldosterone levels at presentation or within the first days after the onset of ST
elevation myocardial infarction (STEMI) are associated with short-term occurrence of major
cardiovascular events (death, heart failure and life-threatening ventricular arrhythmias) [2–4]
and that an early aldosterone blockade in STEMI context was associated with a reduction of
life-threatening ventricular arrhythmias [5,6]. All these data strongly indicate that endogenous
aldosterone can somehow promote ventricular arrhythmias and sudden cardiac death within a
short timeframe; however the underlying exact mechanisms remain largely unknown, particu-
larly whether these rapid effects are MR-mediated [7] or by the activation of distinct membrane
receptors and ion channels [8].
During STEMI context, the “border zone” between normal and ischemic myocardium is a
critical area suggested to promote the early emergence of automatic activity, focal or reentrant
ventricular arrhythmias [9,10]. Recently, we found that aldosterone modulated cardiac ion cur-
rents involved in the holding of the resting membrane potential (RMP) during ischemia-reper-
fusion, with the probable implication of the sarcolemmal-KATP currents [11]. However, the
involvement of other hyperpolarizing currents such as IK1 could not be excluded [12,13].
Therefore, the purpose of this study was, during this critical acute ischemia-reperfusion
phase, to evaluate the electrophysiological impact of aldosterone on IK1 current using an in
vitromodel of rabbit right ventricle mimicking the “border zone” existing between normal and
ischemic/reperfused areas and standard microelectrode technique, followed by cell-attached
patches from freshly isolated rabbit ventricular cardiomyocytes.
Methods
In vitro model of “border zone”
Ethic statement. Experiments were carried out in strict accordance with the European
Commission Directive 86/609/EEC for experimental care and with the recommendations in
the Guide for the Care and Use of Laboratory Animals at the University of Caen. This study
was also conducted with authorization for animal experimentation #14–98 from the local
DDPP (Direction Départementale de la Protection des Populations) and the protocol was
approved by the Committee on the Ethics of Animal Experiments of the University of Caen.
Rabbits were housed at 18~22°C individually in stainless steel cages on racks equipped with
automatic watering systems and free access to food, at the Animal Care Center of Caen Univer-
sity and received daily humane care. All procedures were humanely performed after general
anesthesia has been induced, and all efforts were made to abolish suffering.
Materials. New Zealand white rabbits of either sex weighing 1.5 to 2.0 Kg were euthanized
under anesthesia with sodium pentobarbital 125 mg/kg within the marginal vein. The hearts
were quickly removed after thoracotomy and placed in a cardioplegic solution at room temper-
ature for 30 min. One single thin standard longitudinal strip (16x8 mm) of the right ventricular
free wall was pinned, endocardial surface upward, in a special dual perfusion chamber [14] (S1
Fig, volume of 5 mL) which is bisected by a thin latex membrane. This latex membrane is cen-
trally perforated at its bottom to allow the single ventricular strip to be passed carefully through
and so to be divided into two zones, called the Normal Zone (NZ) and the Altered Zone (AZ),
respectively. This double compartment allowed the two parts of the same and single ventricular
strip to be independently superfused at the rate of 3 mL/min with normal or modified Tyrode’s
solution. The right ventricular base, near the tricuspid valve, was constantly placed in the NZ
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compartment. At the end of each experiment, absence of leakage between the 2 compartments
was tested by a dye injection (methylene blue) in one of the 2 zones. Temperature at the level of
the double chamber, including that of incoming fluids, was controlled and maintained to
36.5 ± 0.5°C by a circulating thermostat-controlled bath (Polystat 5HP, Bioblock, Illkirch,
France).
Superfusion solutions and chemicals. Normal Tyrode’s solution was oxygenated with
95% O2 and 5% CO2 and kept at 37°C. The composition of this Tyrode’s solution was (in
mmol/L): Na+ 135, K+ 4, Ca2+ 1.8, Mg2+ 1, H2PO4
- 1.8, HCO3
- 25, Cl- 117.8, and glucose 11.
The pH was 7.4. The cardioplegic solution used for dissection differed from normal Tyrode’s
by higher glucose (from 11 to 55 mmol/L) and hyperkalemia (from 4 to 30 mmol/L). The mod-
ified, ischemia-simulating Tyrode’s solution differed from normal by elevated K+ concentra-
tion (from 4 to 12 mmol/L), decreased HCO3
- concentration (from 25 to 9 mmol/L) leading to
a decrease in pH (from 7.4 to 7.0), a decrease in PO2 induced by replacement of 95% O2 and
5% CO2 by 95% N2 and 5% CO2, and withdrawal of glucose. All chemicals were purchased
from Sigma Aldrich (Saint Quentin Fallavier, France). All drugs were first diluted in ethanol
and then in Tyrode’s solution. The final concentration of ethanol for all drugs was near 0.1%.
Controls were also treatted with ethanol 0.1% due to ethanol properties on IK1 currents [15].
Data Acquisition and Analysis. The data acquisition and analysis process has been
described in detail previously [16]. The myocardial strips were stimulated at a frequency of 1
Hz via a bipolar silicon-coated steel wire electrode positioned either in the NZ or in the AZ.
Stimulation was applied either in one or the other half of the muscle preparation with a home-
built commutator. Rectangular pulses of 2 ms in duration and twice diastolic threshold inten-
sity (around 2–2.5 V) were delivered by a programmable stimulator (SMP 310, Biologic, Gre-
noble, France). During the protocol, stimulation was stopped whenever sustained spontaneous
arrhythmias occurred. Transmembrane potentials were recorded simultaneously in both myo-
cardial regions by use of intracellular glass microelectrodes pulled from borosilicate filament
tubes (GC 200F-15; Phymep, France) on a single barreled microelectrode puller (Narashige,
distributed by OSI, France). Microelectrodes were filled with KCl 3 mol/L (tip resistance rang-
ing from 10 to 30 MO) and coupled to Ag/AgCl microelectrode holders leading to a home-
built double input stage of a high impedance capacitance-neutralizing amplifier. The two refer-
ence silver—silver chloride electrodes were positioned in the superfusate of each chamber,
close to the preparation. The recordings were displayed on a memory dual-beam storage oscil-
loscope (Gould Instrument Systems Inc, USA). The following AP characteristics were automat-
ically stored at identical time points for the two compartments and measured by a system of
cardiac AP automatic acquisition and processing devices (DATAPAC, Biologic, Grenoble,
France): RMP, AP amplitude (APA), AP duration at 90% of repolarization (APD90), and the
maximal upstroke velocity (Vmax). During both simulated ischemia and reperfusion, spontane-
ous premature ventricular contractions were recorded and were classified in extrasystoles (1 to
3 spontaneous and continuous premature ventricular contractions), salvos (4 to 9 spontaneous
and continuous premature ventricular contractions) and sustained activities ( 10 spontane-
ous and continuous premature ventricular contractions) [16]. To evaluate the ischemia-
induced dispersion of repolarization, APD90 dispersion between NZ and AZ was calculated at
the end of the simulated ischemia period as APD90 NZ- APD90 AZ at 30 min (at the end) of
simulated ischemia. Whenever possible, the same impalement was maintained throughout the
experiment; however, when it was lost, readjustment was attempted. If the readjusted parame-
ters deviated 10% from the previous ones, experiments were continued; otherwise, they were
discarded.
Experimental Protocol (S1 Fig). We used similar experimental protocol than previously
published [16]. During the 120-min stabilization period the right ventricular muscle was
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superfused with normal Tyrode’s solution and stimulated at a frequency of 1 Hz. Thereafter, a
simulated ischemia was induced in 1 compartment (AZ) during 30 min by superfusion with
the modified Tyrode’s solution (simulated ischemia period), while the other compartment
(NZ) remained in normal conditions. At the end of the simulated ischemia, a 30-min reperfu-
sion period was induced by perfusion of normal Tyrode’s solution in the AZ (reperfusion
period). The NZ is perfused with normal Tyrode’s solution during all the experiment and so is
not submitted to the simulated ischemia or to the reperfusion conditions. Unlike, the AZ is
first submitted to 30 min of a simulated ischemia with a modified Tyrode’s solution and then
to the reperfusion period during 30 min with the normal Tyrode’s solution. The administration
of drugs began concomitantly with simulated-ischemia and continued until the end of the
reperfusion period. There was no pretreatment period.
The preparations were randomly assigned to 7 groups: controls (n = 12), aldosterone 100
nmol/L (n = 7), 10 nmol/L (n = 7), aldosterone 10 nmol/L and potassium canrenoate 100
nmol/L (n = 7), aldosterone 10 nmol/L and RU 28318 1 μmol/L (n = 7), potassium canrenoate
100 nmol/L (n = 6), RU 28318 1 μmol/L (n = 6). The n-values given for microelectrode record-
ings are corresponding to the number of independent tissue preparations (or animal used).
Indeed, each animal provided tissue used for only 1 experiment with standard microelectrode
technique.
Cell-attached patch clamp recordings
Isolation of rabbit ventricular myocytes. Rabbit ventricular cardiomyocytes were isolated
by enzymatic digestion procedure modified from previously published protocol [17]. New
Zealand’s white rabbits (1.5 to 2.0 kg) were euthanized by sodium pentobarbital 125 mg/kg
within the marginal vein. Heparin 0.2 mg/kg was added in the same injection to avoid coagula-
tion. The chest was open and the heart quickly removed and mounted on a Langendorff appa-
ratus to be perfused retrogradely with a physiological isolation solution containing (in mmol/
L): NaCl 130, KCl 5.4, NaH2PO4 0.4, MgCl2 1.4, CaCl2 1, HEPES 10, glucose 10, taurine 20 and
creatine 10 (pH at 7.4 with NaOH). When the coronary circulation had cleared of blood, perfu-
sion was continued with Ca-free isolation solution (in which CaCl2 was replaced with 0.1
mmol/L EGTA) for 5 min, followed by perfusion for a further 6–7 min with isolation solution
containing 0.8 mg/ml collagenase (type I; Worthington Biochemical, Lakewood, NJ), and 0.08
mg/ml protease (type XIV). Perfused solutions were maintained at 37°C and bubbled with
100% O2. Ventricles were then excised from the heart, minced, and gently shaken at 37°C in
enzyme-containing solution supplemented with 1% bovine serum albumin. Cells were filtered
from this solution at 5 min intervals, gently centrifuged and resuspended in isolation solution
containing 1 mmol/L CaCl2. Cells were maintained in that solution to be used for patch-clamp
recordings.
Patch-clamp measurements. Single-channel currents from cell-attached patches of
freshly isolated ventricular cardiomyocytes were recorded under voltage clamp at room tem-
perature (20–25°C). An Axopatch 200B (Axon Instruments, Sunnyvale, CA, USA) amplifier
was used, controlled by a Pentium PC connected via a Digidata 1322A A/D converter (Axon
Instruments), which was also used for data acquisition and analysis using Pclamp software
(Axon Instruments). Isolated cells were placed in a bath solution containing (in mmol/L):
NaCl 140, KCl 5.4, NaH2PO4 0.4, CaCl2 1 and HEPES 10 (pH 7.4). Pipette solution contained
(in mmol/L): KCl 145, MgCl2 1, CaCl2 1 and HEPES 10 (pH 7.4). For estimation of ionic selec-
tivity, the 145 mmol/L KCl in the pipette was replaced by 72.5 mmol/L KCl and 72.5 mmol/L
K-glutamate or 72.5 mmol/L KCl and 72.5 mmol/L NaCl. Patch pipettes resistance was
typically 3–4 MO. Single currents were filtered at 1 kHz and digitized at 5 kHz. NPo was
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determined by measuring the mean current Imean for 30s windows and estimating the single
channel current i at the corresponding voltage, according to the I/V relationship. We thus used
the equation (Imean = i NPo). All chemicals were from Sigma-Aldrich (Saint Quentin Fallavier,
France). The n-values given for patch-clamp recordings are corresponding to the number of
cells used. After each result, we specified the number of animals used for the cell recordings.
Statistical Analysis
Results were expressed as mean ± standard error of the mean (SEM). In the two compartments,
each cell served as its own control and significance of differences in absolute values was deter-
mined using analysis of variance (ANOVA) for repeated measures followed by Dunnet’s test as
compared to initial values. Significance of differences between groups was determined using
2-factors ANOVA. The Fisher’s exact test was used for comparison of non-parametric categor-
ical data. Paired or unpaired Student's t-test or non-parametric Wilcoxon test were used as
appropriate to compare data from patch clamp recordings. In all analysis, P<0.05 was consid-
ered statistically significant.
Results
In vitro model of “border zone”
Effects of Aldosterone and mineralocorticoid receptor blockers potassium canrenoate
and RU 28318 on the AP Parameters. In normoxic conditions (NZ), after 1 hour of superfu-
sion, aldosterone was devoid of significant effects on Vmax and on APA. Aldosterone 10 and
100 nmol/L (n = 7 respectively) induced a significant APD90 lengthening (from 156±5 ms to
165±3 ms and 175±6 ms respectively, P<0.05) and a change of RMP (hyperpolarization, from
-84±2 mV to -92±7 mV and -93±5 mV respectively, P<0.05, Table 1, Fig 1). Potassium can-
renoate and RU 28318 alone did not modify any AP parameter.
During the simulated ischemia period (Table 2), aldosterone did not significantly affect
Vmax and APA compared to controls. There was a significant APD decrease in both aldoste-
rone 10 and 100 nmol/L groups (APD90, from 55±3 ms to 40±3 ms and 38±5 ms respectively,
P<0.05). Potassium canrenoate 100 nmol/L significantly decreased Vmax (from 25±5 V/s to
13±3 V/s, P<0.05) without affecting RMP, APA and APD90. RU 28318 alone did not modify
any AP parameter.
During the reperfusion period (Table 2), aldosterone 10 and 100 nmol/L induced a signifi-
cant APD90 lengthening (from 143±4 ms to 156±5 ms and 160±8 ms respectively, P<0.05) and
a RMP hyperpolarization (from -82±2 mV to -89±4 mV and -90±3 mV respectively, P<0.05).
Potassium canrenoate and RU 28318 alone did not modify any AP parameter.
All the effects induced by aldosterone 10 nmol/L were successfully prevented in both NZ
and AZ by adding potassium canrenoate 100 nmol/L but not by adding RU 28318 1 μmol/L
(Tables 1 and 2, Fig 1).
Effects of Aldosterone, Potassium Canrenoate and RU 28318 on APD90 dispersion. At
baseline, in normal conditions, there was no significant APD90 dispersion between the two
regions in all groups (Fig 2). Ischemic-like superfusion induced a significant increase in APD90
dispersion (P<0.0001) in all groups. APD90 dispersion was significantly increased by aldoste-
rone 10 and 100 nmol/L (from 95±4 ms to 116±6 ms and 127±5 ms respectively, P<0.05). This
increase of APD90 dispersion induced by aldosterone 10 nmol/L was prevented by adding
potassium canrenoate 100 nmol/L but not by RU 28318 (respectively 86±3 ms and 112±5 ms
vs 117±5 ms for aldosterone 10 nmol/L, P<0.05). Potassium canrenoate 100 nmol/L and RU
28318 1 μmol/L alone did not significantly affect APD90 dispersion.
Aldosterone Arrhythmogenicity via a MR-Independent IK1 Activation
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Table 1. Electrophysiological Effects of Aldosterone and Aldosterone blockers on AP parameters in Normoxic Conditions (NZ).
Controls Aldosterone Potassium
canrenoate
RU
28318
Potassium canrenoate 100 nmol/L
+ aldosterone 10 nmol/L
RU 28318 1 μmol/L
+ aldosterone 10 nmol/L
10 nmol/
L
100
nmol/L
100 nmol/L 1 μmol/
L
(n = 12) (n = 7) (n = 7) (n = 6) (n = 6) (n = 7) (n = 7)
RMP,
mV
Initial -82 ± 1 -81 ± 2 -82 ± 1 -81 ± 2 -83 ± 1 -82 ± 1 -83 ± 1
30 min -81 ± 1 -90 ± 3a -91 ± 2a -82 ± 3 -84 ± 1 -84 ± 1 -86 ± 1a
60 min -84 ± 2 -92 ± 7a -93 ± 5a -84 ± 1 -85 ± 2 -87 ± 2 -92 ± 1a
APD90,
ms
Initial 143 ± 5 142 ± 2 141 ± 3 141 ± 4 144 ± 6 141 ± 3 142 ± 5
30 min 150 ± 4 156 ± 4 165 ± 4a 143 ± 3 146 ± 7 147 ± 4 152 ± 5
60 min 156 ± 5 165 ± 3a 175 ± 6a 149 ± 2 155 ± 5 156 ± 2 162 ± 3a
Values are mean ± SEM, RMP indicates resting membrane potentiel; APD90, action potential duration at 90% of repolarization.
a P<0.05 vs controls values.
doi:10.1371/journal.pone.0132592.t001
Fig 1. Effects of aldosterone and aldosterone + blockers (RU 28318 and potassium canrenoate) on APD90 and RMP, in the NZ (panel A) and in the
AZ during both simulated-ischemia (panel B) and reperfusion periods (panel C). For sake of clarity and in order not to overload the figure, APD90 and
RMP values are expressed in mean (and not in mean ± SEM). Concerning SEM and statistical significance, please refer to Tables 1 and 2.
doi:10.1371/journal.pone.0132592.g001
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Effects of Aldosterone, Potassium Canrenoate and RU 28318 on the Occurrence of
Spontaneous premature ventricular contractions. At baseline, in normal conditions, spon-
taneous premature ventricular contractions were observed in none of the groups. Results are
summarized in Table 3 and in Fig 3. During simulated ischemia period, aldosterone 10 and 100
nmol/L did not modify premature ventricular contractions occurrence.
During reperfusion period, aldosterone 10 and 100 nmol/L significantly increased the
occurrence of salvos and sustained premature ventricular contractions. This increase in
arrhythmias was prevented by adding potassium canrenoate 100 nmol/L but not by RU 28318
1 μmol/L.
Potassium canrenoate 100 nmol/L and RU 28318 1 μmol/L alone did not significantly affect
premature ventricular contractions occurrence.
Electrophysiological Effects of 1 and 10 μmol/L BaCL2 on the AP parameters in normal
and Ischemic/Reperfused Conditions. We tested 1 and 10 μmol/L Ba2+, a selective IK1
blocker, in our “border zone”model. It induced a rapid AP extinction in the ischemic zone
(lasting to the end of experiment) and a significant APD lengthening in the non-ischemic zone
(Table 4).
Cell-attached patches results
Only one type of spontaneously active channel was observed in 37/40 patches (92.5%), with 3.2
±0.4 channels per patch, while the other patches did not show any activity. Current traces (Fig
4A) showed that its open probability was not affected by voltage, at least from -80 to +20 mV.
No currents were detectable in the outward direction suggesting an inward rectification. The
corresponding current—voltage relationship was linear for the inward currents with a slope
conductance of 30±1 pS and a reversal potential (Er) estimated at +60.3±0.5 mV (n = 5, from 5
different rabbits) suggesting a K+ selectivity of the channel. The anion to cation selectivity was
evaluated by substituting the 145 mmol/L KCl in the pipette solution by 72.5 mmol/L KCl and
72.5 mmol/L K-glutamate. It did not induce any significant change in the reversal potential (Er
= +57.6±2.5 mV; n = 6) indicating a lack of permeability for Cl- (Fig 4A). The selectivity
among cations was evaluated by substituting 72.5 mmol/L KCl in the pipette by the same
Table 2. Electrophysiological Effects of Aldosterone and Aldosterone blockers on AP parameters in Ischemic/Reperfused Conditions (AZ).
Controls Aldosterone Potassium
canrenoate
RU
28318
Potassium canrenoate 100 nmol/L
+ aldosterone 10 nmol/L
RU 28318 1 μmol/L
+ aldosterone 10 nmol/L
10 nmol/
L
100
nmol/L
100 nmol/L 1 μmol/L
(n = 12) (n = 7) (n = 7) (n = 6) (n = 6) (n = 7) (n = 7)
RMP,
mV
Initial -82 ± 1 -81 ± 3 -81 ± 1 -82 ± 6 -83 ± 2 -83 ± 2 -84 ± 1
30 min -52 ± 2 -55 ± 6 -54 ± 2 -56 ± 2 -59 ± 1 -55 ± 3 -53 ± 1
60 min -82 ± 2 -89 ± 4a -90 ± 3a -83 ± 2 -83 ± 1 -83 ± 2 -89 ± 2a
APD90,
ms
Initial 145 ± 5 140 ± 5 140 ± 4 139 ± 4 150 ± 8 141 ± 1 146 ± 6
30 min 55 ± 3 40 ± 3a 38 ± 5a 56 ± 4 56 ± 4 61 ± 4 40 ± 2a
60 min 143 ± 4 156 ± a 160 ± 8a 139 ± 5 144 ± 10 148 ± 4 157 ± 2a
Values are mean ± SEM, RMP indicates resting membrane potential; APD90, action potential duration at 90% of repolarization.
a P<0.05 vs controls values.
doi:10.1371/journal.pone.0132592.t002
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concentration of NaCl. It induced a 17 mV left shift of the reversal potential (Er = +44.4±1.8
mV; n = 5) in accordance with a K+ selectivity of the channel (Fig 4A). The addition of 20
mmol/L Cs2+ (non-selective IK1 blocker) or 100 μmol/L Ba
2+ (selective IK1 blocker) in the
pipette suppressed the 30 pS channel openings (normalized open probability NPo = 2.0±0.4,
n = 10 in control vs NPo = 0±0, n = 5 and 10 respectively, P<0.001) while 10 μmol/L Ba2+ sig-
nificantly reduced the NPo (0.4±0.1, n = 5, P<0.05) (Fig 4B). NPo was not affected by superfus-
ing pinacidil 50 μmol/L (n = 7) or DNP 300 μmol/L (n = 4), excluding IKATP as the
determinant of the active channel recorded in our patches. Altogether, these results were com-
patible with the strong inward rectifier potassium current IK1.
Aldosterone 10 nmol/L was superfused during cell-attached recordings (holding potential =
-40 mV). It produced in all patches a significant increase in channel NPo within 6.2±0.4 min
until the end of the superfusion (1.9±0.4 in control vs 3.0±0.4 with aldosterone; P<0.05,
n = 10) (Fig 5A and 5B) without affecting its single channel conductance (29.8±0.5 n = 6 in
control vs 29.4±1.3 pS n = 5 under aldosterone superfusion) (Fig 5A). Increase in channel NPo
persisted in presence of RU 28318 (NPo relative to the control = 1.4±0.05 under aldosterone
alone, n = 9 vs 1.2±0.1 under aldosterone with RU 28318, n = 7, P<0.05) (Fig 6A and 6B).
Superfusion of RU 28318 alone had no effect on NPo (NPo relative to the control = 1.0±0.1
Fig 2. Representative AP recordings.Representative AP recordings obtained simultaneously in NZ and
AZ in control and in presence of drugs, in same cell, in initial conditions (before initiation of ischemia and drug
superfusion, left), at the end of simulated ischemia (at 30 minutes of experiment, middle) and at the end of
reperfusion (at 60 minutes of experiment, right). APD90 dispersion between NZ and AZ (ΔAPD90) was
measured at the end of the simulated ischemia period as APD90 NZ- APD90 AZ and is expressed as mean
±SEM. Comparisons were made between control group and pharmacological groups. * P<0.05 vs controls.
doi:10.1371/journal.pone.0132592.g002
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under RU 28318 alone, n = 9) (Fig 6A and 6B). Potassium canrenoate superfusion with aldoste-
rone prevented the aldosterone-induced increase in the NPo. 10 different rabbits were used to
assess the aldosterone sensitivity. In our experimental conditions, no other aldosterone-acti-
vated channel type was observed.
Discussion
The main findings of this study may be summarized as follows: 1. In standard microelectrode
experiments, acute superfusion of aldosterone induced a RMP hyperpolarization, decreased
ischemic APD90, increased APD90 dispersion and increased spontaneous premature ventricu-
lar contractions occurrence during the reperfusion period; 2. These effects suggested a modula-
tion of a K+ current involved in the holding of the RMP; 3. Patch-clamp recordings unmasked
an aldosterone-sensitive 30 pS K+-selective current, with pharmacological and biophysical
properties compatible with the strong inward rectifier potassium current IK1; 4. Aldosterone
effects persisted in presence of RU 28318, a specific MR antagonist, and were successfully pre-
vented by potassium canrenoate, a non specific MR antagonist, in both microelectrode and
patch-clamp recordings, thus indicating a MR-independent IK1 activation.
In our microelectrode experiments, aldosterone quickly increased the APD90 dispersion
between ischemic and non-ischemic areas and therefore created an arrhythmia substrate [18].
This effect on dispersion of the repolarization of aldosterone was also demonstrated by Stam-
bler et al. in a rat heart failure model treated with eplerenone [19]. In their study, eplerenone
attenuated HF-related ventricular arrhythmia vulnerability by shorted prolongation of
Table 3. Effect of Aldosterone and Aldosterone blockers on the Incidence of Spontaneous premature ventricular contractions.
Controls Aldosterone
10 nmol/L
Aldosterone
100 nmol/L
Potassium
canrenoate 100
nmol/L
RU 28318
1 μmol/L
Potassium canrenoate
100 nmol/L
+ aldosterone 10 nmol/
L
RU 28318 1 μmol/L
+ aldosterone 10
nmol/L
(n = 12) (n = 7) (n = 7) (n = 6) (n = 6) (n = 7) (n = 7)
Simulated
ischemia period
Extrasystoles (1–3
PVCs)
67 43 43 33 67 57 57
Salvos (4–9
PVCs)
17 14 43 17 33 0 14
Sustained
activities ( 10
PVCs)
17 28 14 0 17 0 14
Reperfusion
period
Extrasystoles (1–3
PVCs)
92 100 86 83 83 86 57
Salvos (4–9
PVCs)
17 71a 71a 17 17 0 57a
Sustained
activities ( 10
PVCs)
17 71a 71a 0 33 0 71a
Values are % of preparations with disturbances.
PVCs means premature ventricular contractions.
a P<0.05 vs controls.
doi:10.1371/journal.pone.0132592.t003
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ventricular repolarization and repolarization dispersion. Human studies have also shown that
endogenous aldosterone can be arrhythmogenic in patients with coronary artery disease without
heart failure by promoting the lengthening of QTc intervals [20] and inducing repolarization
heterogeneity [21], thus providing the substrate for the development of re-entrant ventricular
arrhythmias [18]. Concomitantly, aldosterone also induced triggered activities by increasing
spontaneous premature ventricular contractions occurrence. Interestingly, aldosterone
increased spontaneous premature ventricular contractions occurrence only during the reperfu-
sion period. This may have several explanations. It is known that ventricular arrhythmias occur
preferentially within seconds or minutes of restoration of blood flow to previously ischemic
myocardium or transiently (within few minutes) after a short and sudden ischemia [22]. More-
over, we recently found that aldosterone could also modulate KATP channels [11] which are
known to favor ventricular arrhythmias occurrence during reperfusion via an inability to pre-
vent cell membrane phospholipids injury [23,24]. Finally, these triggered activities could be
linked to cellular Na+/Ca2+ overload, thus aldosterone increases intracellular Ca2+ levels [25].
These deleterious effects of aldosterone observed in standard microelectrode experiments
seemed to involve K+ currents involved in the holding of the RMP and our patch-clamp record-
ings showed an aldosterone-sensitive inward rectifier K+ current. Cardiomyocytes are known to
hold three inward rectifier K+ currents [13]: IK1 that is more prominent in ventricles compare to
atria, IK,Ach that inversely is prominent in atria, and IK,ATP that exhibits a weaker inward rectifi-
cation than others [12]. In our standard microelectrode experiments, we could not distinguish
the own impact of each current and maybe several of these currents were responsible for the
Fig 3. Effects of aldosterone and aldosterone + blockers (potassium canrenoate and RU 28318) on the
incidence of spontaneous premature ventricular contractions during the 30-min of simulated
ischemia and the 30-min of reperfusion. Data are expressed as percentage of preparations with
disturbances. * P < 0.05 vs controls. # P < 0.05 between aldosterone and aldosterone + blockers.
doi:10.1371/journal.pone.0132592.g003
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observed results. We recently shown that aldosterone also modulates KATP channels [11]. How-
ever, in the actually patch-clamp recordings, pinacidil and DNP did not increase NPo of the
aldosterone-sensitive inward rectifier K+ current, thus excluding IKATP identity. IKAch was dis-
carded due to its predominance in atria and therefore the very low probability to register this
current in ventricles [13]. In cardiac tissue, the molecular identity of IK1 currents is Kir2.x with a
conductance range from 10 to 40 pS [12]. Because Kir2.1 was reported to be functionally
expressed in ventricular rabbit myocytes and exhibits a single channel conductance of 30 pS, it
more likely corresponds to the channel recorded in our preparation [12]. While IK1 is mostly
considered to be active during the hyperpolarization of the membrane, it also participates in the
AP, immediately after upstroke and during phase 3 repolarization, providing a repolarizing out-
ward current [26]. Therefore, modulation of IK1 would likely have a profound effect on cardiac
excitability and arrhythmogenesis [27]. The role of Kir2.1 in ventricular arrhythmia vulnerabil-
ity has been highlighted by the recently described Andersen’s syndrome [28], in the guinea pig
heart model of ventricular fibrillation [29], in a transgenic mouse model [30] and recently in
human KCNJ2 mutation [31]. Therefore, IK1 activation during ischemia-reperfusion context
may have a deleterious impact on ventricular arrhythmogenesis.
Unfortunately, in our standard microelectrode experiments, it was not possible to highlight
a possible protective role of IK1 current blockade by Ba
2+ on deleterious effects induced by aldo-
sterone. It was demonstrated that 10 μmol/L Ba2+ partially but selectively inhibit IK1 [32]. At
Table 4. Electrophysiological Effects of 1 and 10 μmol/L BaCL2 on the AP parameters in normal (NZ, left panel) and Ischemic/Reperfused Condi-
tions (AZ, right panel).
NZ AZ
Controls BaCl2 Controls BaCl2
10 μmol/L 1 μmol/L Controls 10 μmol/L 1 μmol/L
(n = 12) (n = 3) (n = 3) (n = 12) (n = 3) (n = 3)
RMP, mV
Initial -82 ± 1 -79 ± 2 -82 ± 3 -82 ± 1 -79 ± 2 -84 ± 2
5 min -80 ± 1 -73 ± 3 -83 ± 2 -60 ± 2 ND -69 ± 8
10 min -79 ± 1 -73 ± 6 -77 ± 3 -56 ± 2 ND ND
30 min -81 ± 1 -77 ± 2 -77 ± 2 -52 ± 2 ND ND
60 min -84 ± 2 -77 ± 3 -79 ± 5 -82 ± 2 ND ND
Vmax, V/s
Initial 279 ± 17 288 ± 22 282 ± 31 279 ± 17 243 ± 12 295 ± 24
5 min 260 ± 16 285 ± 14 265 ± 22 85 ± 13 ND 159 ± 34
10 min 235 ± 21 259 ± 12 238 ± 33 65 ± 11 ND ND
30 min 255 ± 26 241 ± 15 246 ± 16 24 ± 5 ND ND
60 min 251 ± 20 254 ± 23 285 ± 25 251 ± 20 ND ND
APD90, ms
Initial 145 ± 5 143 ± 13 137 ± 8 145 ± 5 143 ± 8 138 ± 6
5 min 148 ± 5 149 ± 12 143 ± 10 104 ± 4 ND 96 ± 8
10 min 147 ± 5 151 ± 8 148 ± 5 77 ± 5 ND ND
30 min 150 ± 4 157 ± 7 155 ± 7 55 ± 4 ND ND
60 min 156 ± 5 184 ± 12 168 ± 11 143 ± 4 ND ND
Values are mean ± SEM, RMP indicates resting membrane potential; Vmax, maximal upstroke velocity; APD90, action potential duration at 90% of
repolarization;
NZ, normal zone; AZ, altered zone; ND, not determinable.
doi:10.1371/journal.pone.0132592.t004
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this concentration, Ba2+ does not affect IKr, IKs, Ito or IKATP but depresses selectively IK1 by
about 60% [33]. When we tested this concentration in our microelectrode experiments, it
induced a rapid AP extinction in the ischemic zone (lasting to the end of experiment) and a sig-
nificant APD lengthening in the non-ischemic zone (Table 4). 1 μmol/L Ba2+ had the same
effects and we did not test lower concentrations because of the loss of IK1 inhibition that would
have resulted. This ischemic AP extinction may be explained by the strong ischemia and depo-
larization induced by our simulated ischemia added to Ba2+ effects. Interestingly, concomi-
tantly to this "non-viable" ischemic AP, we did not observe premature ventricular contractions.
Clearly, there are major differences between isolated cells and tissues which may well account
for these discepancies.
Our results might indicate that aldosterone induced arrhythmogenesis by a MR-indepen-
dent IK1 activation during myocardial ischemia-reperfusion context. Some studies have shown
that deleterious effects of increased concentrations of aldosterone may be related to slow geno-
mic mechanisms (within weeks), through activation of specific cytosolic MR [7] and to rapid
non-genomic mechanisms (within minutes to days), through activation of membrane recep-
tors and ion channels [8,34]. Wehling and colleagues showed that aldosterone at nanomolar
concentrations produced rapid, nongenomic and MR-independent effects in a variety of tissues
[35]. However, evidence has been forthcoming that these rapid nongenomic effects of aldoste-
rone on cardiomyocytes are mediated via the classical MR [36]. In recent clinical trials [5,37],
the deleterious impact of aldosterone on sudden cardiac death and ventricular arrhythmias
occurred within a short timeframe, too short, apparently, to be attributed to MR-dependent
mechanisms, in accordance with our results. In our experiments, this rapid and deleterious IK1
activation induced by aldosterone superfusion, in both standard electrodes and patch-clamp
recordings, persisted in presence of RU 28318 and were successfully prevented by potassium
canrenoate. Although the beneficial effects of MR antagonists are now well established in clini-
cal practice [6,38–40], there is some debate about their specificity, particularly regarding
Fig 4. Cell-attached patches.Cell-attached patches from freshly isolated rabbit ventricular cardiomyocytes showing a 30 pS K+-selective channel, inward
rectifier, with pharmacological and biophysical properties consistent with the IK1 current. A: Current voltage relationship (i/ΔVm) recorded in cell-attached
conditions with 145 mmol/L KCl (black squares) or 72.5 mmol/L KCl and 72.5 mmol/L K-glutamate (open circles) or 72.5 mmol/L KCl and 72.5 mmol/L NaCl
(open triangles) in the pipette. Typical single channel recordings are provided for several voltages for 145 mmol/L KCl (left pannel) or 72.5 mmol/L KCl and
72.5 mmol/L K-glutamate (right pannel). B: NPo of the basally active 30 pS channel in control condition (145 mmol/L KCl in the pipette) or with addition in the
pipette of whether 20 mmol/L Cs2+, 10 or 100 μmol/L Ba2+. Numbers in bars are the numbers of experiments.
doi:10.1371/journal.pone.0132592.g004
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Fig 5. A:Current voltage relationship (i/ ΔVm) recorded in cell-attached condition with 145 mmol/L KCl in the patch pipette under control (dark squares and
dark line) and after aldosterone superfusion (10 nmol/L) (open triangles and dotted line)B: Single channel NPo in control and during aldosterone superfusion
in 10 cells. Open circle and dotted lines represent individual recordings. Mean is represented by dark squares and wide dark lines.C: Representative single
channel current activity under control and under aldosterone superfusion (10 nmol/L) from the same patch membrane (ΔVm = -40 mV).
doi:10.1371/journal.pone.0132592.g005
Fig 6. A: Single channel NPo under aldosterone superfusion (10 nmol/L), RU 28318 (1μmol/L) and
aldosterone (10 nmol/L) with RU 28318 (1μmol/L) relative to the NPo in control B:Representative experiment
showing the single channel NPo in function of the time under control followed by RU 28318 superfusion
(1 μmol/L) and aldosterone (10 nmol/L) with RU 28318 (1 μmol/L) in the same patch membraneC: Single
channel NPo under Potassium Canrenoate superfusion (100 nmol/L) and aldosterone (10 nmol/L) with
Potassium Canrenoate (100 nmol/L) relative to the NPo in control. Numbers in bars are the numbers of
experiments.*P<0.05; ns: non-significant.
doi:10.1371/journal.pone.0132592.g006
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potassium canrenoate and spironolactone, which can also antagonize the glucocorticoid and
progesterone receptors; in contrast, RU 28318 specifically antagonizes the MR [41]. Although
K+ currents, particularly IK1 and IKATP, seem to be responsible for a critical part of aldosterone
arrhythmogenesis in our standard microelectrode experiments, they are probably not the only
currents involved. Indeed, the RMP was shifted towards more negative values (Table 1), while
APD90 was prolonged. Neither of these effects can be explained by an increase in solely IK1 and
IKATP. An increased IK1 alone may have some impact on RMP, but unlikely to the extent as
shown here [33]. Furthermore, increased IK1 and IKATP add to the repolarization capacity and
would shorten the AP [42]. Therefore, it is highly probable that additional ionic currents were
affected by aldosterone treatment in our “border zone” experiments. Activation of aldosterone/
MR deeply modulates cardiac electrical activity and leads to ventricular arrhythmias. The
increase of MR expression directly impact on T-type calcium channels activity, decrease IKr
activity and impaired the activity of the ryanodine receptor in mouse atrial HL1 cells [43]. Ex
vivo, aldosterone increases the L-type calcium current in neonatal rat cardiomyocytes [44,45]. In
vivo, cardiomyocyte-specific MR overexpression in transgenic mice induces ionic remodeling
with a decrease of the outward potassium current (Ito) activity and an increase in L-type Ca
channel activity which is associated with ventricular extrasystoles and an increase in sensitivity
to the triggering of ventricular arrhythmia [46]. Aldosterone is also known to block IKs and IKr
currents and increase INa and IK,ATP current [11,47,48]. These currents are probably mainly
responsible for AP prolongation and could also participate in the pro-arrhythmic effects induced
by aldosterone. Interestingly, we did not observed RMP hyperpolarization during the simulated
ischemia period. It is probably due to a competition with the strong depolarization induced by
the modified ischemia-simulating Tyrode solution. Finally, Kir2 have pH dependence depending
on the isoforms. This is especially relevant due to isoform differences between species [49]. As
ischemia-reperfusion and aldosterone both affect tissue pH, this could explain that the RMP
hyperpolarization induced by aldosterone in our experiments was not observed in other prepa-
rations (mouse ventricular myocytes) [47] and might be related to species-specific differences.
Study Limitations
The study was performed in rabbit myocardium because although rabbit myocardium differs
from human myocardium, the main ionic currents involved are qualitatively similar (com-
pared to rat or mice myocardium) [50] and because our in vitromodel of "border zone"
requires the use of a right ventricular strip measuring at least 13–14 mm (mean rabbit right
ventricular strip length of 16x8 mm used in our preparations). We did not use left ventricular
myocardium because of its excessive thickness not compatible with our experimental model
associated with the risk of poor perfusion in the center of the tissue that could cause ischemia.
Unfortunately, we were unable to inhibit IK1 in our “border zone”model and therefore we can-
not directly link the arrhythmogenicity observed in this model to a role of IK1 (Table 4). This
right ventricular in vitromodel could induce an intramural ischemia since the tissue is super-
fused rather than perfused. This, added to the fact that we practiced recordings at 37°C, could
explain the non-significant APD90 and RMP time-variation observed during experiments in
the NZ of the control group (Fig 1). IK1 current activation is known to decrease with tempera-
ture [51,52] so we could therefore suppose that in our patch-clamp experiments conditions
(room temperature), the aldosterone-induced IK1 current activation could be underestimated.
Whereas RU 28318 is a specific and selective MR antagonist, potassium canrenoate, the active
metabolite of spironolactone, is also able to block glucocorticoid and progesterone receptors,
along with other ion currents [48]. Potassium canrenoate also has a major effect on cardiac
excitability and inotropism [53,54]. These properties could introduce a bias in our results.
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Finally, we used RU 28318 as a specific MR antagonist and not eplerenone because when we
performed our experiments, eplerenone was unfortunately not freely available. As our experi-
ments seem to indicate a MR-independent pathway, the experiments using RU 28318 cannot
be strictly considered as their own positive controls.
Conclusion
In this in vitromodel mimicking the “border zone” existing between normal and ischemic/
reperfused regions, aldosterone induced deleterious electrophysiological effects including an
arrhythmia substrate (increasing APD90 dispersion) and triggered activities (increasing prema-
ture ventricular contractions occurrence on reperfusion). In microelectrode experiments, these
effects might be related with the modulation of K+ currents involved in the holding of the RMP.
Our patch-clamp recordings showed an aldosterone-sensitive 30 pS K+-selective channel, with
pharmacological and biophysical properties consistent with the strong inward rectifier K+ cur-
rent IK1. These deleterious effects persisted in presence of RU 28318, a specific MR antagonist,
and were successfully prevented by potassium canrenoate, a non specific MR antagonist, in both
microelectrode and patch-clamp recordings, thus indicating a MR-independent IK1 activation.
This new highlighted mechanism is in line with current clinical data [2,4,5] and could help to
understand underlying mechanisms explaining the increase of ventricular arrhythmia and sud-
den cardiac death occurrence concomitant with high aldosterone levels during STEMI.
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S1 Fig. The double compartment tissue bath used for the experiments. The volume chamber
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adjacent portion with the altered, ischemia-simulating solution.
(TIF)
S2 Fig. Experimental protocol. NZ means Normal Zone; AZ altered Zone.
(TIF)
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